Table 1.
Immune responses to the quadrivalent HPV vaccine measured by cLIA and total IgG: seropositivity and GMTs (total N=76), 28 and 48 weeks after vaccination1
| ART Status | Participants (N) |
IgG LIA seropositivity N (%) |
cLIA seropositivity N (%) |
Total IgG GMT (mMu/ml) Mean (Std. Dev.) |
cLIA GMT (mMu/ml) Mean (Std. Dev.) |
|
|---|---|---|---|---|---|---|
| Anti-HPV6 | ||||||
| 28 Weeks (n=30) | All | 30 | 30 (100.0) | 30 (100.0) | 640.3 (780.7) | 869.8 (1003.5) |
| ART | 10 | 10 (100.0) | 10 (100.0) | 946.3 (1051.4) | 1294.4 (1342.2) | |
| No ART | 20 | 20 (100.0) | 20 (100.0) | 487.2 (576.9) | 657.5 (735.7) | |
| 48 Weeks (n=29) | All | 29 | 28 (96.6) | 29 (100.0) | 231.0 (302.2) | 341.1 (373.1) |
| ART | 9 | 9 (100.0) | 9 (100.0) | 334.6 (402.0) | 491.9 (507.7) | |
| No ART | 20 | 19 (95.0) | 20 (100.0) | 181.9 (239.3) | 273.2 (284.51) | |
| Anti-HPV11 | ||||||
| 28 Weeks (n=50) | All | 50 | 49 (98.0) | 49 (98.0) | 521.5 (644.0) | 1001.6 (1244.0) |
| ART | 16 | 16 (100.0) | 16 (100.0) | 682.2 (818.1) | 1521.9 (1868.9) | |
| No ART | 34 | 33 (97.1) | 33 (97.1) | 443.7 (537.8) | 749.2 (694.8) | |
| 48 Weeks (n=46) | All | 46 | 43 (93.5) | 45 (97.8) | 129.9 (198.3) | 319.0 (471.2) |
| ART | 17 | 15 (88.2) | 16 (94.1) | 219.5 (311.4) | 521.6 (742.8) | |
| No ART | 29 | 28 (96.6) | 29 (100.0) | 82.0 (63.6) | 207.1 (130.3) | |
| Anti-HPV16 | ||||||
| 28 Weeks (n=41) | All | 41 | 41 (100.0) | 40 (97.6) | 2790.3 (4234.8) | 3314.8 (3675.2) |
| ART | 13 | 13 (100.0) | 13 (100.0) | 4223.9 (4985.5) | 5046.2 (4482.3) | |
| No ART | 28 | 28 (100.0) | 27 (96.4) | 2124.7 (3751.2) | 2481.1 (2961.0) | |
| 48 Weeks (n=40) | All | 40 | 40 (100.0) | 39 (97.5) | 753.1 (1336.0) | 1044.5 (1594.6) |
| ART | 14 | 14 (100.0) | 14 (100.0) | 1301.2 (2015.0) | 1822.2 (2431.4) | |
| No ART | 26 | 26 (100.0) | 25 (96.2) | 458.0 (643.7) | 609.0 (522.7) | |
| Anti-HPV18 | ||||||
| 28 Weeks (n=55) | All | 55 | 55 (100.0) | 52 (94.6) | 552.0 (694.8) | 647.4 (917.8) |
| ART | 16 | 16 (100.0) | 16 (100.0) | 759.1 (694.3) | 978.7 (1270.0) | |
| No ART | 39 | 39 (100.0) | 36 (92.3) | 467.0 (685.8) | 500.1 (680.9) | |
| 48 Weeks (n=52) | All | 52 | 51 (98.1)2 | 38 (73.1)2 | 125.8 (140.7) | 224.2 (383.3) |
| ART | 19 | 18 (94.7) | 14 (73.7) | 166.5 (172.69) | 308.7 (528.84) | |
| No ART | 33 | 33 (100.0) | 24 (72.7) | 103.6 (116.88) | 175.0 (267.29) |
1
A McNemar’s test for paired data was used to compare seropositivity as measured by total IgG LIA and cLIA for each HPV type at weeks 28 and 48.
2
p=.0002; otherwise no significant differences (p < .05) between IgG LIA and cLIA with respect to seropositivity; GMTs are not comparable across the two assays so were not compared.